Obeticholic acid, a potent activator of the above-mentioned FXR already registered for the treatment of primary biliary cholangitis, has been tested for use in NASH patients in the FLINT (Farnesoid X Receptor Ligand Obeticholic Acid in NASH Treatment) trial. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.